The Brussels Desk · IndependentBrussels desk
CommissionFriday, 20 November 2026 · 2 min read

EU Approves First Biosimilar Under EMA's Streamlined Clinical Rules

Biocon's pertuzumab secures European marketing authorization, validating a faster regulatory pathway for complex medicines

By Aldo Verheyen · Filed Friday, 20 November 2026 · Last updated 13:00 CET

Share

What happened

Biocon has received European Union marketing authorization for its pertuzumab biosimilar, marking the first time a biosimilar has won approval under the European Medicines Agency's (EMA) tailored clinical approach.

A biosimilar is a biological medicine developed to be equivalent in quality, safety, and efficacy to an already authorized reference biologic. Pertuzumab, a monoclonal antibody primarily used in targeted cancer therapies, belongs to an expensive category of biological medicines that often puts heavy strain on public hospital formularies. The authorization grants market clearance across all EU member states.

Why it matters

For national healthcare providers and patients, biological treatments represent some of the steepest costs in modern medicine. When patents expire and biosimilars enter the market, pricing competition typically brings those expenses down and widens patient access.

The broader regulatory precedent is just as consequential. Under the EMA's tailored clinical approach, regulators can reduce or refine certain routine clinical study requirements when extensive analytical and laboratory comparisons already prove the biosimilar matches the reference product. Eliminating redundant clinical hurdles shortens development timelines and slashes costs, theoretically accelerating the arrival of cheaper alternatives to European clinic shelves without lowering scientific safety bars.

The Brussels angle

While corporate communiqués routinely celebrate an 'EU approval', the procedure is a neat institutional division of labour. The Amsterdam-based European Medicines Agency handles the rigorous scientific and clinical assessment, but the final, legally binding marketing authorization is issued by the European Commission in Brussels.

This centralized procedure remains one of the single market's most tangible practical achievements. Instead of wrestling with 27 distinct national drug regulators, pharmaceutical manufacturers run a single gauntlet to access more than 400 million citizens at once. In a regulatory ecosystem rarely accused of moving too quickly, the EMA's willingness to streamline clinical trial burdens demonstrates that even EU procedural machinery can occasionally choose efficiency over redundant paperwork.

What happens next

While the Commission's centralized marketing authorization provides a single regulatory passport to sell the medicine throughout the union, it does not put boxes on pharmacy shelves immediately.

Healthcare delivery and pharmaceutical spending remain the jealous prerogatives of national capitals. Biocon must now enter member-state-by-member-state pricing and reimbursement negotiations with individual health ministries and tender boards. Only once those 27 separate domestic price haggles conclude will the drug actively enter routine clinical use across European hospitals.

emabiosimilarspharmaceuticalshealthcaresingle market

Written from these sources

Facts are extracted from primary institutional material and written independently by The Gazette desk.

Brussels Correspondent · European Commission

Aldo Verheyen

Aldo Verheyen is The Gazette's Brussels Correspondent, covering the European Commission, its College and the art of the leaked draft. He has reported from the Berlaymont since 2019 and translates proposals into plain English before they become law.

More from Aldo Verheyen →

The Brief

Brussels, decoded, every morning. What happened, what it means, one good dry joke.